Literature DB >> 12000695

Comparison of forward planned conformal radiation therapy and inverse planned intensity modulated radiation therapy for esthesioneuroblastoma.

A Zabel1, C Thilmann, I Zuna, W Schlegel, M Wannenmacher, J Debus.   

Abstract

The purpose of this study was to compare dose distribution of inverse planned intensity modulated radiation therapy (IMRT) with that of conformal radiation therapy (SCRT) in the treatment of esthesioneuroblastoma, and to report initial clinical results. 13 patients with esthesioneuroblastoma were planned both with IMRT and SCRT using complete three-dimensional data sets. A target dose of 60 Gy was prescribed. We performed a detailed dose volume histogram analysis. Dose coverage was equal in both plans while dose distribution was more conformal to the target volume with IMRT. Mean and maximum dose of the brain stem, chiasm, optic nerves and orbits were lower using IMRT than SCRT. The reduction was significant regarding orbit and optic nerve (p<0.05). IMRT was superior in sparing of organs at risk compared with SCRT. The additional sparing by IMRT was positively correlated to the size of the target volume, which was evident with target volumes above 200 cm3. Treatment time was approximately 20 minutes per fraction using IMRT compared with 15 minutes per fraction using SCRT. We conclude that IMRT is both feasible and a valuable tool for more conformal dose distribution in the treatment of esthesioneuroblastoma and to spare organs at risk that are in critical relationship to the tumour. This advantage could be seen especially well in complex shaped target volumes above 200 cm3. Thus, using IMRT, risk of complications may be minimized and local tumour control may be increased.

Entities:  

Mesh:

Year:  2002        PMID: 12000695     DOI: 10.1259/bjr.75.892.750356

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  3 in total

1.  [Intensity modulated radiotherapy (IMRT) of head and neck tumors. Increased biological effectiveness in high-risk situations by "integrated boost" therapy].

Authors:  D Milanovic; F Lohr; K Götte; B Dobler; B Hermann; K Hörmann; F Wenz
Journal:  HNO       Date:  2004-08       Impact factor: 1.284

Review 2.  Esthesioneuroblastoma.

Authors:  Heidi D Klepin; Kevin P McMullen; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2005-11

Review 3.  Meningioma: current treatment options and future directions.

Authors:  Kevin P McMullen; Volker W Stieber
Journal:  Curr Treat Options Oncol       Date:  2004-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.